Resume Writer - Need One ?
The Following Text Is An Unformatted Professional Resume Sample
From The Writers At Resumes Guaranteed


ORDER YOUR OWN LETTER-PERFECT, JOB-WINNING RESUME AND IT WILL BE COMPLETED AS SOON AS YOU NEED!
Click HERE!



Yyyyyy x. yyyyyy

0000 xxxxxx xxxx , xxxx , xxxxx 00000

Phonexxx-xxx-xxxx

abc@xyz.com

 

Professional Summary

 

Experienced Research Scientist eager to contribute talents in pharmacology and research biology toward supporting a dynamic company in achieving business objectives.  Considerable experience in planning, coordinating, managing and completing a broad range of research projects specializing in biology and in vivo toxicology.  Keen organizational, interpersonal, decision-making, and analytical skills.  Additional strengths are:

         Adept at analyzing drug safety through in-depth toxicology assessments.

         Proficiency in designing experiments, ensuring protocol compliance, administering quality control to ensure accuracy of data, and maintaining lab instruments and equipment.

         Dependable and extremely productive; reliably ensure and perform a thorough and high quality job in all endeavors.

         Ability to establish effective and cohesive working relationships with all levels of an organization.

         Polished multi-tasking abilities; gracefully balance competing priorities.

 

Professional Experience

 

Algos Preclinical Services, St Paul, Minnesota                                                              2009 to Present

Lead Scientist

         Successfully and reliably complete all protocol driven mandates within strict timelines while conducting in vivo rodent pharmacology experiments for domestic and international clients in support of pain discovery programs.

         Demonstrate exemplary versatility in executing experiments such as acute and chronic inflammatory assays, neuropathic pain assays, GI functional assays, and drug delivery system evaluations. 

         Appreciated for actively coaching, training, mentoring and advising junior staff.

         Increased company revenue by fostering a major account within first four months with Algos.

 

Adolor Corporation, Exton, PA                                                                    2001 to 2009

Research Scientist II

  • Directed full-scope in vivo experiments in rats and mice from experimental design with appropriate control groups and set up, to data collection, analysis, and interpretation.
  • Spearheaded acute antinociceptive assays, inflammation induced-hyperalgesia assays, and behavioral assays to assess side effects or other potential therapeutic benefits of novel compounds.
  • Research expertise contributed to advancing 10 drug development candidates, 4 INDs, and the approval of alvimopan (Enteregâ) for postoperative ileus by the U.S. Food and Drug Administration (FDA).
  • Established and validated experimental protocols from literature, and effectively modified procedures when appropriate.
  • Compiled and presented research findings at group, and National Society meetings.
  • Served as liaison to the DEA and as Controlled Substance Program Administrator.
  • Demonstrated commitment to compliance and accountability as active member of IACUC (Institutional Animal Care and Use Committee) as well as Employee Health and Safety Committee.

 

Continued

 

 

 

Yyyyyy x. yyyyyy

 

Professional Experience continued

 

 

Schering-Plough Corporation, Lafayette, NJ                                                                    1999 to 2001

Study Director / Senior Team Associate

  • Led specialized toxicology efforts as Study Director & Acute Team Coordinator, successfully managing GLP/non-GLP in vivo acute, and short-term studies vital to drug development efforts.
  • As Senior Team Associate for general toxicology research, oversaw GLP drug safety studies in large and small animals, particularly for the desloratidine (Clarinexâ), and ezetimibe (Zetiaâã) programs.
  • Efficiently directed all project phases including protocol development, study design, documentation, data tabulation and audits, and final report preparation and submission.
  • Presented with two Going the Extra Mile awards for displaying exceptional performance, and consistently surpassed all project deadlines.

 

Nycomed-Amersham Imaging PLC, Wayne, PA                                         1994 to 1999

Senior Research Scientist

         Directed over 65 studies in a six-month-time period, leveraging outstanding leadership talents to coordinate team in inoculating large and small animal tumor models, monitoring their progress, and evaluating body versus tumor uptake of radiolabeled and non-radiolabeled ligands.

         Developed extraction techniques (from tissue matrices) to determine utility of imaging agents for x-ray, MRI, ultrasound, gamma, and light imaging modalities by expertly using analytical equipment.

         Conducted binding and inhibition assays using radiolabeled and cold peptides on cells and cell fragments by exhibiting precise attention to detail.

         Developed dog anti-tetanus-toxoid ELISA (enzyme-linked immunosorbent assay).

         Maintained primary human and animal tumor cell cultures for in vivo implantation vital to imaging vascularity differences of high potential metastatic vs. low potential, and non-metastatic tumors.

         Managed and documented all phases of GLP drug safety studies in large and small animals, tabulating complex data, and preparing reports by drawing upon significant organizational skills in documenting. This was accomplished while functioning as Study Director on several occasions.  

 

Additional Experience includes:

Research Scientist, Sterling Winthrop Pharmaceuticals Research Division, Collegeville, PA

 

Education

 

M.S. in Health/Public Health, Concentration in Public Health/Toxicology, West Chester University,

West Chester, PA, 2003

 

B.S. in Animal Science, Minor in Agricultural Economics, Cornell University, Ithaca, NY, 1982

 

Certified LATG (Laboratory Animal Technologist), American Association for Laboratory Animal Science, 1991

 

Technical Expertise

 

Electronic Data Capture/Management Systems: Topaz/Granite, Datatox, Xybion, Places, Labcat.

 

Office & Statistical Software: MS Word, Excel, PowerPoint, GraphPad Prism™, SPSS.

 

 

 

Yyyyyy x. yyyyyy  ~ Addendum

 

Professional Affiliations

 

Member, Society of Toxicology, Society for Neuroscience

 

Publications

 

  1. Wiant, D.D., B. Le Bourdonnec, R.E. Dolle, R.T. Windh and P.J. Little. Activity of ADL5859 and ADL 5747, two novel delta-opioid receptor agonists, in antidepressant assays. Neuropsychopharmaco-logy. In press.
  2. Le Bourdonnec, B., R.T. Windh, L.K. Leister, Q.J. Zhou, C.W. Ajello, M. Gu, G.-H. Chu, P.A. Tuthill, W.M. Barker, M. Koblish, D.D. Wiant, T.M. Graczyk, S. Belanger, J.A. Cassel, M.S. Feschenko, B.L. Brogdon, S.A. Smith, M.J. Derelanko, S. Kutz, P.J. Little, R.N. DeHaven, D.L. DeHaven-Hudkins and R.E. Dolle.  Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N, N-diethyl-3-hydroxy-4-(spiro[chromene-2,4 -piperidine]-4-yl) benzamide (ADL5747). J. Med. Chem. 52(18): 5685-5702, 2009.
  3. Le Bourdonnec, B., R.T. Windh, C.W. Ajello, L.K. Leister, M. Gu, G.-H. Chu, P.A. Tuthill, W.M. Barker, M. Koblish, D.D. Wiant, T.M. Graczyk, S. Belanger, J.A. Cassel, M.S. Feschenko, B.L. Brogdon, S.A. Smith, D.D. Christ, M.J. Derelanko, S. Kutz, P.J. Little, R.N. DeHaven, D.L. DeHaven-Hudkins and R.E. Dolle.  Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N, N-diethyl-4-(5-hydroxyspiro[chromene-2,4 -piperidine]-4-yl)benzamide (ADL5859).  J. Med. Chem. 51(19): 5893-5896, 2008.
  4. Le Bourdonnec, B., W.M. Barker, S. Belanger, D.D. Wiant, N.C. Conway-James, J.A. Cassel, T.J. O Neill, P.J. Little, R.N. DeHaven, D.L. DeHaven-Hudkins and R.E. Dolle.  Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu-opioid receptor antagonists with improved opioid receptor selectivity profiles. Bioorg. Med. Chem. Lett. 18(6): 2006-2012, 2008.
  5. Acknowledgement in: Bergeron R.M., L. Li, J.M. Petruska and T. Haushalter. The Effect of Diet Optimization on the Pattern of Rat Food Consumption. Schering-Plough Research Institute, Lafayette, NJ. 2001.
  6. Hennesy R., J. Hincks, V. Reddy, E. Harling, D.D. Wiant, and V. Sansone. The Effect of Jugular Bleeding on Clinical Chemistry and Hematological Parameters in Sprague-Dawley Rats. The Toxicologist. 14: 230, 1994.

 

Abstracts

 

  1. Saeui, C.T., G.-H. Chu, I.F. Sellitto, C.W. Ajello, L.K. Leister, T.M. Graczyk, M. Koblish, D.D. Wiant, C.J. LaBuda, P.J. Little, R.N. DeHaven, B. Le Bourdonnec, R.E. Dolle.  Novel imipramine derivatives as potent norepinephrine and/or serotonin reuptake inhibitors with reduced off-target activities. 238th American Chemical Society National Meeting, Washington, DC, August 16-20, 2009.
  2. Sellitto, I.F., C.W. Ajello, L.K. Leister, C.T. Saeui, G.-H. Chu, T.M. Graczyk, M. Koblish, D.D. Wiant, C.J. LaBuda, P.J. Little, R.N. DeHaven, B. Le Bourdonnec, R.E. Dolle.  Amitriptyline analogs with improved off-target profile: utility for the treatment of pain. 238th American Chemical Society National Meeting, Washington, DC, August 16-20, 2009.
  3. Wiant, D.D., N. Conway-James, K. Worm, Q.J. Zhou, P.J. Little.  GI effects of a novel peripherally selective cannabinoid agonist. International Narcotics Research Conference, St. Paul, MN, July 9-14, 2006.
  4. Wiant, D.D., C.J. LaBuda, B. Le Bourdonnec, G.-H. Chu, M. Gu, Q.J. Zhou, P.A. Tuthill, C.W. Ajello, P.J. Little.  Antidepressant-like effects of novel delta opioid receptor agonists in rats. 35th Annual Meeting of the Society for Neuroscience, Washington, DC, November 12-16, 2005.

 

 

 

 

  1. Conway-James N.C., D.D. Wiant, M. Koblish, C.J. LaBuda, G.J. Stabley, K. Worm, Q.J. Zhou, P.J. Little.  In vivo characterization of a non-classical biaryl cannabinoid, ADC00007609. 15th Annual International Cannabinoid Research Society Meeting, Clearwater, FL, June 23-28, 2005.
  2. Conway-James N.C., D.D. Wiant, P.J. Little, P.A. Tuthill, R.E. Dolle.  The anti-ileus effect of the I-NOS inhibitor AR-C10222 in rats. 34th Annual Meeting of the Society for Neuroscience, San Diego, CA, October 23-27, 2004.
  3. Koblish M., C.J. LaBuda, N.C. Conway-James, D.D. Wiant, P.A. Tuthill, R.E. Dolle, P.J. Little.  Anti-inflammatory effects of the I-NOS inhibitor AR-C10222 in rodents. 34th Annual Meeting of the Society for Neuroscience, San Diego, CA, October 23-27, 2004.
  4. Wiant D.DThe significance of elevated serum aminotransferase levels in the absence of hepatic necrosis: preclinical predictive value and relevance to human risk. Annual Meeting of the Society for Toxicology, Baltimore, MD, March 21-25, 2004.
  5. Le Bourdonnec, B., R.E. Dolle, P.J. Little, D.L. DeHaven-Hudkins, D.D. Wiant, N.C. Conway-James, G.J. Stabley, S. Belanger, J.A. Cassel, R.N. DeHaven, J.M. Sutton, T. Harrison, D. Neighbour.   Comparison of the pharmacological profile of the opioid antagonists naltrexone and 14-beta-amino-N-cyclopropylmethyl-7,8-dihydronormorphinone in vitro and in vivo. 225th National Meeting of the American Chemical Society, New Orleans, LA, 2003.
  6. Wiant, D.D., L.C. Sharpless, D.L. DeHaven-Hudkins, P.J. Little.  Anti-ileus effects of ADL 10-0102, a novel kappa agonist, in rats.  International Narcotics Research Conference, Pacific Grove, CA, July 9-14, 2002.
  7. Little P.J., S. Gottshall, M. Koblish, S. Long, D.D. Wiant, D. DeHaven-Hudkins.  Antagonism of opioid-induced inhibition of GI transit and secretion by Alvimopan (ADL 8-2698), a peripherally restricted opioid antagonist. Adolor Corporation, Malvern PA, 2002.
  8. Wiant D.D., L.C. Sharpless, D.L. DeHaven-Hudkins, P.J. Little.  Anti-ileus effects of ADL 10-0102, a novel kappa agonist, in rats. International Narcotics Research Conference (joint mtg. with the International Cannabinoid Research Society), Pacific Grove, CA, July 9-14, 2002.
  9. Conway-James N.C., D.D. Wiant, L.C. Sharpless, P.J. Little. Intrastrain differences in the EMG response to colorectal distension in rats. Experimental Biology Symposium (ASPET), New Orleans, LA, April 20-24, 2002.

<< Previous           Back to Sitemap           Next >>

Remember: Hire Us To Write YOUR New Resume
And We GUARANTEE That If You’re Not Working In 60 Days Or Less,
We’ll Revise Your Resume, Refund Your Money,
AND Give You $50 EXTRA!

Click HERE!